DK1760088T3 - Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler - Google Patents

Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler

Info

Publication number: DK1760088T3
Authority: DK; Denmark
Prior art keywords: molecules; tumour; present; relates; hla
Prior art date: 2005-09-05

Application number

DK05019254T

Other languages

English (en)

Inventor

Joern Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2008-06-09

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2008-06-09 Application granted granted Critical

2008-06-09 Publication of DK1760088T3 publication Critical patent/DK1760088T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK05019254T 2005-09-05 2005-09-05 Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler DK1760088T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (en)	2005-09-05	2005-09-05	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules

Publications (1)

Publication Number	Publication Date
DK1760088T3 true DK1760088T3 (da)	2008-06-09

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DK07007915.7T DK1806359T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK07007914.0T DK1806358T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK05019254T DK1760088T3 (da)	2005-09-05	2005-09-05	Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
DK09011319.2T DK2135878T3 (da)	2005-09-05	2006-09-05	Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK06791838.3T DK1922335T3 (da)	2005-09-05	2006-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK07007915.7T DK1806359T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK07007914.0T DK1806358T3 (da)	2005-09-05	2005-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK09011319.2T DK2135878T3 (da)	2005-09-05	2006-09-05	Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
DK06791838.3T DK1922335T3 (da)	2005-09-05	2006-09-05	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler

Country Status (23)

Country	Link
US (6)	US10196432B2 (da)
EP (6)	EP1806358B1 (da)
JP (1)	JP5627180B2 (da)
KR (3)	KR101386827B1 (da)
CN (3)	CN103059104B (da)
AT (5)	ATE461215T1 (da)
AU (2)	AU2006289290B2 (da)
BR (1)	BRPI0615462A2 (da)
CA (2)	CA2929252A1 (da)
CY (5)	CY1107973T1 (da)
DE (4)	DE602005020046D1 (da)
DK (5)	DK1806359T3 (da)
EA (1)	EA013876B1 (da)
ES (5)	ES2341802T3 (da)
HK (2)	HK1183678A1 (da)
HR (2)	HRP20100128T1 (da)
NO (1)	NO340870B1 (da)
NZ (2)	NZ566104A (da)
PL (5)	PL1806359T3 (da)
PT (5)	PT1806358E (da)
SI (5)	SI1760088T1 (da)
UA (1)	UA98295C2 (da)
WO (1)	WO2007028574A2 (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1806358E (pt) *	2005-09-05	2010-05-28	Immatics Biotechnologies Gmbh	Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
SI2567707T1 (sl)	2007-07-27	2017-01-31	Immatics Biotechnologies Gmbh	Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku
CA2694805C (en) *	2007-07-27	2014-09-09	Immatics Biotechnologies Gmbh	Immunogenic epitopes of tumour-associated antigens
PT2660248E (pt)	2007-07-27	2015-10-12	Immatics Biotechnologies Gmbh	Nova imunoterapia para tumores neuronais e cerebrais
CN104356225B (zh)	2007-08-20	2018-02-13	肿瘤疗法科学股份有限公司	Cdh3 肽以及含有cdh3 肽的药剂
WO2009059011A2 (en) *	2007-11-01	2009-05-07	Mayo Foundation For Medical Education And Research	Hla-dr binding peptides and their uses
ES2554981T3 (es)	2008-03-27	2015-12-28	Immatics Biotechnologies Gmbh	Nueva inmunoterapia contra tumores neuronales y cerebrales
PT2113253E (pt)	2008-04-30	2010-06-15	Immatics Biotechnologies Gmbh	Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
NO2119726T3 (da)	2008-05-14	2015-05-23
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
PT2172211E (pt) *	2008-10-01	2015-03-09	Immatics Biotechnologies Gmbh	Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
HUE025796T2 (hu) *	2009-01-28	2016-05-30	Ind Tech Res Inst	Diabéteszes nefropátiához kapcsolt vizelet és szérum biomarkerek
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
KR20130126671A (ko)	2010-12-14	2013-11-20	이매틱스 바이오테크놀로지스 게엠베하	전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법
ES2841983T3 (es) *	2011-03-23	2021-07-12	Hutchinson Fred Cancer Res	Método y composiciones para inmunoterapia celular
TWI777194B (zh) *	2013-08-05	2022-09-11	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
IL300761A (en)	2013-08-05	2023-04-01	Immatics Biotechnologies Gmbh	Innovative immunotherapy against several tumors, such as lung cancer, including NSCLC
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en)	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
IL248203A0 (en)	2014-05-09	2016-11-30	Immatics Biotechnologies Gmbh	Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PT3626729T (pt)	2014-12-23	2021-11-03	Immatics Biotechnologies Gmbh	Novos péptidos e combinações de péptidos para uso na imunoterapia contra o carcinoma hepatocelular (chc) e outros cancros
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
IL308735A (en)	2015-07-01	2024-01-01	Immatics Biotechnologies Gmbh	New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP4321172A2 (en)	2015-07-06	2024-02-14	immatics biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI803835B (zh)	2015-08-28	2023-06-01	德商英麥提克生物技術股份有限公司	用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
MY198087A (en)	2015-10-05	2023-07-31	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PE20230343A1 (es)	2015-12-11	2023-03-01	Immatics Biotechnologies Gmbh	Peptidos que estimulan respuestas inmunitarias antitumorales
TWI765875B (zh)	2015-12-16	2022-06-01	美商磨石生物公司	新抗原辨識、製造及用途
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh)	2016-03-01	2023-07-04	伊玛提克斯生物技术有限公司	用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
BR112018070183A2 (pt) *	2016-03-31	2019-04-16	Neon Therapeutics, Inc.	neoantígenos e métodos de seu uso
MY197258A (en)	2016-04-06	2023-06-08	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG11201808629UA (en)	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
CR20180551A (es)	2016-04-21	2019-02-12	Immatics Biotechnologies Gmbh	Inmunoterapia contra el melanoma y otros tipos de cáncer
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
CA3027124A1 (en) *	2016-06-10	2017-12-14	Umc Utrecht Holding B.V.	Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
TW202304970A (zh)	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
AR110857A1 (es)	2017-01-27	2019-05-08	Immatics Biotechnologies Gmbh	Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
SG11201906198PA (en)	2017-01-27	2019-08-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA47367B1 (fr)	2017-01-27	2023-06-28	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
CN110248672A (zh) *	2017-02-06	2019-09-17	中央研究院	重组蛋白及其用途
US11427614B2 (en)	2017-04-10	2022-08-30	Immatics Biotechnologies Gmbh	Peptides and combination thereof for use in the immunotherapy against cancers
MA49122A (fr)	2017-04-10	2021-03-24	Immatics Biotechnologies Gmbh	Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
SG10202100326SA (en)	2017-04-10	2021-02-25	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
EA201992416A1 (ru)	2017-04-10	2020-02-25	Имматикс Байотекнолоджиз Гмбх	Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
TW201906859A (zh)	2017-07-07	2019-02-16	德商英麥提克生物技術股份有限公司	用於肺癌（包括 nsclc、sclc 和其他癌症）免疫治療的新型肽和肽組合物
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
AU2018332654B2 (en)	2017-09-18	2022-07-21	S & P Ingredient Development, Llc	Low sodium salt substitute with potassium chloride
EP3694532A4 (en)	2017-10-10	2021-07-14	Gritstone Oncology, Inc.	IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
JP2021503897A (ja)	2017-11-22	2021-02-15	グリットストーンオンコロジーインコーポレイテッド	新生抗原のためのジャンクションエピトープ提示の低減
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
BR112020016176A2 (pt)	2018-02-09	2022-02-22	Immatics Us Inc	Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
AU2019227813A1 (en) *	2018-02-27	2020-10-01	Gritstone Bio, Inc.	Neoantigen identification with pan-allele models
EP3539562A1 (en) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immunotherapeutic peptides
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en)	2018-09-17	2024-04-02	Immatics Biotechnologies Gmbh	B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
US20200384028A1 (en)	2019-06-06	2020-12-10	Immatics Biotechnologies Gmbh	Sorting with counter selection using sequence similar peptides
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
JP2022543059A (ja) *	2019-07-30	2022-10-07	ユニバーシティーヘルスネットワーク	Ｔ細胞受容体及びその使用方法
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) *	2022-10-14	2024-04-18	Guangdong Tcrcure Biopharma Technology Co., Ltd.	Peptide vaccines against glioma and uses thereof
CN117720620A (zh) *	2023-12-13	2024-03-19	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (da) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
FI86437C (fi)	1978-12-22	1992-08-25	Biogen Inc	Foerfarande foer framstaellning av polypeptider med de antigena egenskaperna hos ett hepatitis b- virusantigen.
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en)	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
EP0636175A1 (en) *	1992-04-03	1995-02-01	La Jolla Cancer Research Foundation	Decorin fragments and methods of inhibiting cell regulatory factors
DE69332485T2 (de) *	1992-08-11	2003-11-13	Harvard College	Immunmodulierende peptide
CA2175380A1 (en) *	1993-10-29	1995-05-04	Lan Bo Chen	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
WO1996003144A1 (en)	1994-07-27	1996-02-08	The Council Of The Queensland Institute Of Medical Research	Polyepitope vaccines
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
PT879282E (pt)	1996-01-17	2003-11-28	Imp College Innovations Ltd	Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
WO1998031818A2 (en) *	1997-01-21	1998-07-23	Human Genome Sciences, Inc.	Tace-like and matrilysin-like polypeptides
US6316213B1 (en) *	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
DE59813016D1 (de) *	1997-10-15	2005-09-22	Pharis Biotec Gmbh	Cadherin derived growth factor und seine verwendung
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
AU2001236589A1 (en) *	2000-02-04	2001-08-14	Aeomica, Inc.	Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
AU2001278076A1 (en) *	2000-07-26	2002-02-05	Applied Genomics, Inc.	Bstp-5 proteins and related reagents and methods of use thereof
AU2001295582A1 (en)	2000-12-20	2002-07-01	GlaxoSmithKline Biologicals (s.a.)	Tumour-related antigens
WO2002078516A2 (en)	2001-03-30	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
US7705120B2 (en) *	2001-06-21	2010-04-27	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002323120A1 (en) *	2001-08-13	2003-03-03	Dana-Farber Cancer Institute, Inc.	Periostin-based diagnostic assays
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
US20050100554A1 (en) *	2002-02-14	2005-05-12	Amanda Jackson	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
WO2004014867A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20070224201A1 (en) *	2002-10-02	2007-09-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2003304203A1 (en) *	2002-10-29	2005-01-04	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
CA2527571A1 (en) *	2003-05-29	2004-12-09	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2008500952A (ja) *	2003-07-15	2008-01-17	ジェノバ・リミテッド	心臓血管障害で減少する分泌ポリペプチド種
EP1757940A1 (en)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
ATE440107T1 (de) *	2005-09-05	2009-09-15	Immatics Biotechnologies Gmbh	Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
PT1806358E (pt) *	2005-09-05	2010-05-28	Immatics Biotechnologies Gmbh	Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
EP1795599A1 (en) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Methods for generating antigen-specific effector T cells

2005
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es active Active
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de active Active
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Not-in-force
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Not-in-force
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es active Active
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Not-in-force
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es active Active
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de active Active
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de active Active
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
2006
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en active Application Filing
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active IP Right Cessation
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active IP Right Cessation
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active IP Right Cessation
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
2007
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-03-09 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2013
- 2013-10-02 HK HK13111197.3A patent/HK1183678A1/xx not_active IP Right Cessation
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
EP1760088B1 (en)	2008-03-05
CA2621389C (en)	2016-07-19
ATE388164T1 (de)	2008-03-15
SI1760088T1 (sl)	2008-06-30
US20080206218A1 (en)	2008-08-28
DK1806358T3 (da)	2010-06-28
JP5627180B2 (ja)	2014-11-19
AU2006289290B2 (en)	2010-11-25
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
ATE532795T1 (de)	2011-11-15
US20100040590A1 (en)	2010-02-18
US10618945B2 (en)	2020-04-14
CY1112186T1 (el)	2015-12-09
CY1110051T1 (el)	2015-01-14
EP1922335A2 (en)	2008-05-21
US7833970B2 (en)	2010-11-16
SI1806358T1 (sl)	2010-06-30
ES2337399T3 (es)	2010-04-23
ES2341295T3 (es)	2010-06-17
EP2138509A1 (en)	2009-12-30
DE602005005196T2 (de)	2008-06-26
HRP20110981T1 (hr)	2012-02-29
CN101287754A (zh)	2008-10-15
EA013876B1 (ru)	2010-08-30
PT1760088E (pt)	2008-05-14
CY1107973T1 (el)	2013-09-04
US7807642B2 (en)	2010-10-05
JP2010502173A (ja)	2010-01-28
PT1922335E (pt)	2010-03-03
CY1109849T1 (el)	2014-09-10
ATE451388T1 (de)	2009-12-15
PL1922335T3 (pl)	2010-05-31
HK1220709A1 (zh)	2017-05-12
SI1922335T1 (sl)	2010-04-30
ES2341802T3 (es)	2010-06-28
EP2135878A1 (en)	2009-12-23
KR20130019033A (ko)	2013-02-25
KR20130019034A (ko)	2013-02-25
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
CA2621389A1 (en)	2007-03-15
UA98295C2 (ru)	2012-05-10
HRP20100128T1 (hr)	2010-04-30
NZ588813A (en)	2011-06-30
EP1806358A2 (en)	2007-07-11
EP1806359A1 (en)	2007-07-11
CN103059104A (zh)	2013-04-24
ES2302546T3 (es)	2008-07-16
US20160115212A1 (en)	2016-04-28
SI2135878T1 (sl)	2012-03-30
DK1806359T3 (da)	2010-06-14
DE602005005196D1 (de)	2008-04-17
US20080207520A1 (en)	2008-08-28
EP1806358B1 (en)	2010-03-17
US7833969B2 (en)	2010-11-16
US10196432B2 (en)	2019-02-05
SI1806359T1 (sl)	2010-06-30
PL1806358T3 (pl)	2010-08-31
WO2007028574A2 (en)	2007-03-15
HK1183678A1 (en)	2014-01-03
KR101386827B1 (ko)	2014-04-17
PT2135878E (pt)	2012-01-05
PT1806358E (pt)	2010-05-28
NO340870B1 (no)	2017-07-03
EP1806358A3 (en)	2007-10-03
DE602005020047D1 (de)	2010-04-29
ATE461214T1 (de)	2010-04-15
EP2135878B1 (en)	2011-11-09
AU2010236029A1 (en)	2010-11-18
AU2006289290A1 (en)	2007-03-15
CA2929252A1 (en)	2007-03-15
KR101386355B1 (ko)	2014-04-17
NZ566104A (en)	2011-04-29
CN103059104B (zh)	2015-10-28
DE602005020046D1 (de)	2010-04-29
EP1760088A1 (en)	2007-03-07
EP1806359B1 (en)	2010-03-17
ES2373907T3 (es)	2012-02-10
EA200800677A1 (ru)	2008-08-29
AU2010236029B2 (en)	2012-06-28
WO2007028574A9 (en)	2008-05-02
DK2135878T3 (da)	2012-02-27
DE602006011030D1 (de)	2010-01-21
KR101386790B1 (ko)	2014-04-21
WO2007028574A3 (en)	2007-05-24
US20080206217A1 (en)	2008-08-28
NO20081683L (no)	2008-04-04
EP1922335B1 (en)	2009-12-09
PT1806359E (pt)	2010-05-25
PL2135878T3 (pl)	2012-06-29
CY1110187T1 (el)	2015-01-14
US20080206216A1 (en)	2008-08-28
CN101287754B (zh)	2013-02-13
ATE461215T1 (de)	2010-04-15
KR20080052643A (ko)	2008-06-11
DK1922335T3 (da)	2010-04-19

Publication	Publication Date	Title
HK1220709A1 (zh)	2017-05-12	混雜地結合於人類白細胞抗原類分子的腫瘤相關肽
HRP20110240T1 (en)	2011-05-31	Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
SI1794190T1 (sl)	2009-12-31	Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope